Overview

Evaluation of the Effect of Pramlintide on Satiety and Food Intake

Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
This is a single center, randomized, blinded, placebo-controlled, two-period, cross-over study to evaluate the effect of pramlintide on satiety and food intake in normal-weight and obese non-diabetic subjects and in insulin-treated subjects with type 1 and type 2 diabetes.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Islet Amyloid Polypeptide
Pramlintide